Select Page

Off-label use: Article in the American Journal of Ophthalmology

Together with UC Davis Ophthalmology faculty member, Ala Moshiri, M.D., Ph.D., I published a commentary in the American Journal of Ophthalmology regarding the challenges to making off-label use of products a standard of care in retina therapies in ophthalmology.   This continues a theme from a previous paper regarding this issue with antibiotics in cataract surgery.  While off-label use and compounding medications on a patient by patient basis is supported by U.S. code, a more general policy for standard of care creates a narrow ledge for patients and physicians. 

Recent Posts

Gary D. Novack, PhD, president of PharmaLogic Development

Dr. Novack speaking at ASCRS 2014

Dr. Novack talked in two symposia at the Glaucoma 360 event of the Glaucoma Research Foundation in San Francisco.

PharmaLogic sponsor a northern California bicycle riding team “Caballo Rojo

UCSC Chancellor George Blumenthal and Foundation President Ken Doctor thank Dr. Novack for his service to UCSC.

Dr. Novack on floor of California State Assembly with Assemblymember Beall (D-San Jose)

Dr. Novack addresses European Glaucoma Society on Generic Drugs

Dr. Novack with Dr. Wiley Chambers (FDA/CDER), Dr. Ellen Strahlman (CMO GSK), and Dr. Malvina Eydelman (FDA/CDRH) at the Glaucoma 360 event.

Dr. Novack speaking at International Symposium on Ocular Pharmacology and Therapeutics, Vienna, Austria

Dr. Elizabeth Moyer and Dr. Novack at ophthalmology workshop European Medicines Agency

Dr. Novack presents young investigator award at ASPET to Stephanie Piecewicz of MIT